Treatment of immune checkpoint inhibitor–associated myocarditis with abatacept and ruxolitinib: a case report
DOI:
https://doi.org/10.60103/phc.v28.e943Keywords:
polimedicados; pediátricos; conciliación; medicaciónAbstract
Introduction: Myocarditis, as an adverse effect associated with treatment using immune checkpoint inhibitors, is a rare but potentially life-threatening complication, particularly in patients who are unresponsive to glucocorticoids.
Case presentation: A 44-year-old woman with triple-negative breast cancer undergoing neoadjuvant treatment with pembrolizumab, doxorubicin and cyclophosphamide who, after three cycles of treatment, developed severe myocarditis with ventricular arrhythmias and persistent elevated troponin T levels; an immunomodulatory strategy aimed at improving the prognosis in such situations was proposed.
Assessment: Despite initial management with glucocorticoids, mycophenolate mofetil and supportive measures, she presented with clinical deterioration.
Results: The immunosuppressive treatment was switched to abatacept and ruxolitinib, resulting in progressive improvement and haemodynamic stabilisation.
Conclusions: This case highlights the use of abatacept and ruxolitinib as a strategy in glucocorticoid-refractory myocarditis, with significant implications for clinical practice.
Downloads
References
Ogunniyi KE, Djunadi TA, Adewara O, Babawale I, Akinmoju OD, Olaiya VO, et al. Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence. Cardiovasc Toxicol. 2025 Sep;25(9):1381-1410. doi: 10.1007/s12012-025-10038-y
Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, et al. Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position State-ment. JAMA Oncol. 2026 Jan 1;12(1):90-99. doi: 10.1001/jamaoncol.2025.4543
Schulz-Menger J, Collini V, Gröschel J, Adler Y, Brucato A, Christian V, et al. ESC Scientific Docu-ment Group. 2025 ESC Guidelines for the management of myocarditis and pericarditis. Eur Heart J. 2025 Oct 22;46(40):3952-4041. doi: 10.1093/eurheartj/ehaf192
Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II triaL for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025 Feb;118(2):106-115. doi: 10.1016/j.acvd.2024.12.005
Wadden E, Lai C, Grivas P, Bhatia S, Portuguese AJ, Salem JE, et al. Successful treatment of im-mune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. Eur Heart J Case Rep. 2025 Feb 17;9(2):ytaf019. doi: 10.1093/ehjcr/ytaf019
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 María Montero Lázaro, Sergio Maganto Garrido, Alicia Martín Roldán, María Elena Cárdaba García, Silvia Fernández Peña, Alba Fijó Prieto
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).
